Nuvaring

NuvaRing is a combined hormonal contraceptive vaginal ring containing etonogestrel 11.7 milligrams and ethinylestradiol 2.7 milligrams per ring. It is licensed in the United Kingdom for the prevention of pregnancy in adult women. NuvaRing belongs to the combined hormonal contraceptive group of medicines. It delivers a continuous, steady hormone release directly through the vaginal wall, releasing approximately 120 micrograms of etonogestrel and 15 micrograms of ethinylestradiol per 24 hours. NuvaRing is worn as a flexible vaginal ring for three weeks, then removed for one week to allow a withdrawal bleed. This page provides information about how NuvaRing works, how to insert and use it correctly, what to expect, and important safety information.

For women who find daily pill-taking difficult to sustain, or who experience gastrointestinal side effects on oral contraception, NuvaRing offers a different approach. Because hormones are absorbed through the vaginal wall rather than the gut, NuvaRing is not affected by vomiting or diarrhoea in the way that oral pills can be. This makes it a practical alternative to the combined pill for eligible women. A prescription from a registered clinician is required before NuvaRing can be supplied.

NuvaRing is a flexible, transparent plastic ring approximately 54 millimetres in diameter. You insert it yourself into the vagina, where it sits comfortably and delivers hormones continuously throughout the three-week wearing period. You do not need to think about contraception again until you remove it on day 22.

The ring contains two active hormones:

1. Etonogestrel: a synthetic third-generation progestogen and the active metabolite of desogestrel
2. Ethinylestradiol: a synthetic oestrogen

These are the same hormones found in many combined oral contraceptive pills, but at lower delivered daily doses. The transmucosal delivery route bypasses first-pass liver metabolism, so effective circulating hormone levels are achieved with less total hormone input than equivalent oral preparations.

NuvaRing is manufactured by Organon Pharma UK Limited. Each ring is for single use only. One ring covers one complete monthly contraception cycle.

How NuvaRing Compares to the Pill

The combined pill requires a tablet taken at roughly the same time every day. A missed or late tablet can compromise contraceptive protection. NuvaRing removes that daily requirement. Once inserted, steady hormone release continues automatically for three weeks. This means that for most women, NuvaRing's real-world effectiveness more closely reflects its theoretical effectiveness compared with a daily pill, where human compliance is the main variable.

NuvaRing is also unaffected by gastrointestinal illness. Vomiting or diarrhoea reduces the absorption of oral hormones. Transvaginal delivery is not subject to this risk, so stomach upset does not compromise your contraceptive protection.

NuvaRing works through three mechanisms, all driven by its steady release of etonogestrel and ethinylestradiol.

Stopping Ovulation

The hormones suppress the pituitary signals that would normally trigger an egg to be released from the ovary. Without the luteinising hormone surge, ovulation does not occur. This is the primary and dominant contraceptive mechanism. When NuvaRing is used correctly throughout the cycle, ovulation suppression is consistent and reliable.

Thickening Cervical Mucus

Etonogestrel increases the thickness of cervical mucus, making it significantly harder for sperm to travel through. This secondary mechanism provides added protection during periods of hormonal transition, such as at the start of a new ring cycle.

Altering the Uterine Lining

The combined hormonal environment changes the endometrial lining, reducing its readiness for implantation. This is a third layer of contraceptive protection. In practice, ovulation suppression is so consistent with correct ring use that this mechanism rarely becomes relevant.

Why Steady Hormone Release Matters

Standard combined pills produce a daily peak in circulating hormones shortly after ingestion, followed by a gradual fall before the next dose. NuvaRing's transmucosal delivery produces a much flatter and more stable hormone profile. This steady state is maintained throughout the wearing period. Some women find that the absence of daily hormonal peaks and troughs results in a more consistent experience across the cycle, though individual responses vary.

Inserting the Ring

Compress the ring between your fingers and gently push it into the vagina. The exact position inside the vagina does not affect how well it works. Push it back as far as is comfortable. Most women cannot feel NuvaRing once it is in place. If you can feel it and find it uncomfortable, push it a little further in.

Insert the ring on the correct starting day and leave it in place for exactly 21 days. Remove it on the same day of the week it was inserted, three weeks later. After the seven-day ring-free interval, insert a new ring on day 29.

When to Start

1. No previous hormonal contraception: insert on day one of your period for immediate protection. Starting between days two and five is possible but requires barrier contraception for the first seven days.
2. Switching from a combined pill: insert NuvaRing no later than the day after your pill-free interval ends, or after the last inactive tablet if your pill had placebo days.
3. Switching from a progestogen-only pill: insert on any day and use a barrier method for seven days.
4. Switching from an injectable: insert when the next injection would have been due.

The Ring-Free Week

Remove the ring on day 22. During the following seven days, hormone levels fall and a withdrawal bleed typically occurs. This bleed is not a true menstrual period. It is a response to the hormone withdrawal. Insert a new ring on day 29, whether or not the bleed has finished. The ring-free interval must never exceed seven days. If it does, ovarian activity may resume before the new ring re-establishes hormonal suppression.

If the Ring Comes Out

If NuvaRing slips out and has been outside the vagina for fewer than three hours, rinse it with cool or lukewarm water and reinsert it straight away. Your protection is maintained.

If the ring has been out for more than three hours, the next step depends on which week of the cycle you are in. In weeks one and two, reinsert immediately and use barrier contraception for the following seven days. In week three, discard the ring: either start a new ring at once, skipping the ring-free week, or begin the ring-free interval now and insert a new ring after seven days. If unprotected sex occurred while the ring was out, seek advice about emergency contraception without delay.

Three-hour rule: if NuvaRing has been out of the vagina for more than three hours, contraceptive protection may be reduced. Reinsert it and use a barrier method for seven days. Contact your prescriber or pharmacist if you are unsure what to do.

Each NuvaRing contains etonogestrel 11.7 milligrams and ethinylestradiol 2.7 milligrams in total. During the three-week wearing period, it releases approximately 120 micrograms of etonogestrel and 15 micrograms of ethinylestradiol per 24 hours.

The ethinylestradiol delivery rate of approximately 15 micrograms per day is lower than the oestrogen dose in most combined oral contraceptives, which typically contain between 20 and 35 micrograms of ethinylestradiol per tablet. Effective contraceptive circulating levels are achieved at this lower dose because transmucosal delivery bypasses the liver.

One Ring, One Cycle

Each ring is designed for a single 21-day use. One ring covers one complete monthly contraception cycle: three weeks in, one week out. After removal, the ring is discarded. A new ring begins the next cycle. NuvaRing is for monthly contraception; there is no long-acting format and no generic equivalent available in the UK.

The following information is based on the current UK SmPC for NuvaRing. Not everyone experiences side effects. Read the Patient Information Leaflet in full before using NuvaRing.

Common Side Effects

Common side effects include headache, nausea, mood changes, reduced libido, and vaginal discomfort or increased discharge. Some women and their partners notice the ring during intercourse. Irregular spotting or changes to the withdrawal bleed pattern, particularly in the first cycle, are also common and usually settle.

Less Common Side Effects

1. Weight changes
2. Breast tenderness
3. Contact lens intolerance
4. Chloasma: patches of darker skin on the face, made worse by sun exposure

Serious Signs to Act on Immediately

Stop using NuvaRing and seek urgent medical help if you experience:

1. Sudden chest pain, breathlessness, or coughing up blood
2. Swelling, pain, redness, or warmth in one leg only
3. Sudden severe headache, visual disturbance, speech difficulty, or weakness down one side of your body
4. Severe abdominal pain
5. Yellowing of your skin or the whites of your eyes

These may indicate a blood clot, stroke, or liver problem.

Blood Clot Risk

All combined hormonal contraceptives carry a small increased risk of venous thromboembolism compared with women not using hormonal contraception. Etonogestrel is a third-generation progestogen. NuvaRing sits in the same VTE risk category as desogestrel and gestodene-containing combined pills, which is somewhat higher than levonorgestrel-based pills, according to MHRA guidance. Your prescriber assesses your individual risk factors before recommending NuvaRing.

Medicines That Affect NuvaRing

Enzyme-inducing medicines speed up the breakdown of etonogestrel and ethinylestradiol, reducing their circulating levels. These include rifampicin, certain antiepileptic medicines such as phenytoin, carbamazepine, phenobarbital, and topiramate, some HIV antiretrovirals, and St John's Wort. Tell your prescriber about every medicine, supplement, and herbal product you take.

NuvaRing Is Not Suitable If You:

1. Have ever had a blood clot: deep vein thrombosis, pulmonary embolism, stroke, or heart attack
2. Have migraine with aura
3. Have uncontrolled high blood pressure
4. Have active or past liver disease or liver tumours
5. Have or have had breast cancer or another hormone-sensitive cancer
6. Are pregnant
7. Are breastfeeding a baby under six weeks old
8. Smoke and are 35 or older
9. Have diabetes with established vascular complications
10. Have conditions affecting the vagina that may make ring use impractical, such as significant uterovaginal prolapse

NuvaRing May Be Appropriate If You:

1. Are a healthy adult woman with no contraindications to combined hormonal contraception
2. Find daily pill-taking difficult to maintain consistently
3. Have experienced nausea or other gastrointestinal side effects on oral combined pills, as NuvaRing bypasses the gut
4. Are comfortable with self-insertion of a vaginal device
5. Are looking for a monthly contraception method as a pill alternative with steady hormone release
6. Have no personal or family history of blood clots, stroke, or cardiovascular disease

Talk to Your Prescriber First If You:

1. Smoke and are under 35
2. Have a BMI above 30
3. Have a first-degree family member who had a blood clot before the age of 50
4. Have migraines without aura
5. Are planning long-haul travel or face extended immobility
6. Have recurrent vaginal infections or conditions affecting vaginal health

Pharmacy Planet is a GPhC registered UK online pharmacy. Every NuvaRing prescription is issued following a clinical consultation reviewed individually by a registered prescriber. The consultation is the primary step in the process. A prescription is the possible outcome, not a guaranteed result.

Because NuvaRing is a vaginally inserted device rather than an oral tablet, your prescriber assesses both your general suitability for combined hormonal contraception and your suitability for the ring format specifically. Your health history, current medicines, VTE risk factors, any gynaecological history, and your comfort with self-insertion all form part of that assessment.

The outcome may be a prescription for NuvaRing, a recommendation for a different hormonal method, a referral for an in-person review, or a suggestion that a different approach to contraception is more appropriate for your individual circumstances. Completing the questionnaire opens the clinical conversation. It does not determine the outcome. Repeat prescriptions follow the same individual review with no automatic renewal.

NuvaRing is stored by the pharmacy at 2°C to 8°C before you receive it. Once in your possession, store it at room temperature not exceeding 30°C, in its original sealed foil pouch, away from direct sunlight and heat. It can be kept at room temperature for up to four months or until the expiry date on the packaging, whichever comes first.

After removal, place the used ring back in the resealable foil pouch and dispose of it in your household waste. Do not flush it down the toilet. Each ring contains residual hormones after use. If you have questions about safe disposal, your pharmacist can advise.

This reference guide compares the contraceptive preparations available at Pharmacy Planet, grouped by delivery method and formulation type. Every preparation is a Prescription Only Medicine. A registered prescriber will review your individual health profile, contraceptive history, and risk factors before recommending any preparation. This table is a clinical reference, not a recommendation.

The table below compares the vaginal ring and transdermal patch available at Pharmacy Planet. Both deliver combined hormonal contraception without daily tablet-taking, using different delivery routes and dose profiles.

Important: This comparison is for general information only and does not replace medical advice. A prescriber will decide which treatment is suitable for you following an online consultation.

NuvaRing is a different category of contraception from the pills covered elsewhere on our site. Prescribing it requires a prescriber to consider the vaginal delivery route, patient suitability for self-insertion, the absence of daily compliance requirements, and the specific VTE risk classification of etonogestrel as a third-generation progestogen. These are not boxes to tick quickly. At Pharmacy Planet, our prescribers give every NuvaRing consultation the individual attention it requires.

If NuvaRing is not clinically appropriate for you at this point, the prescriber will explain why and discuss alternatives. We do not issue prescriptions to meet supply targets. The clinical assessment exists to protect you, and we take that seriously.

1. Organon Pharma UK Limited. NuvaRing 11.7 mg/2.7 mg vaginal delivery system – Summary of Product Characteristics. Available at: www.medicines.org.uk/emc. Accessed May 2026.
2. Faculty of Sexual and Reproductive Healthcare (FSRH). Combined Hormonal Contraception – Clinical Guidance. Available at: www.fsrh.org. Accessed May 2026.
3. NHS. Contraceptive vaginal ring. Available at: www.nhs.uk/conditions/contraception/contraceptive-vaginal-ring. Accessed May 2026.
4. British National Formulary (BNF). Etonogestrel with ethinylestradiol. Available at: bnf.nice.org.uk. Accessed May 2026.
5. MHRA. Combined hormonal contraceptives and venous thromboembolism – updated guidance. Available at: www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency. Accessed May 2026.